443388

BPC 157 (GEPPPGKPADDAGLV)

GEPPPGKPADDAGLV; BPC 157; BPC-157; BPC157; Bpc 15; Bpc-15; Bpc15; Booly protection compound 15; BPC 157 TFA; BPC 157 trifluoroacetic acid; L-Valine, glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-, trifluoroacetic acid

BPC 157 is shown to have strong beneficial effect on intestinal and liver lesions. BPC 157 is a pentadecapeptide with clinical relevance to the treatment of inflammatory bowel disease. It has been shown to heal lesions in experimental models of bowel disease, and is also an anti-inflammatory agent that has been shown to have clinical relevance in patients with congestive heart failure. BPC 157 has been shown to inhibit inflammation by blocking the production of pro-inflammatory mediators such as nitric oxide, prostaglandins, and leukotrienes. It also suppresses the production of pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β). BPC 157 also down-regulates genes that are involved in liver fibrosis, which may account for its efficacy in patients with liver cirrhosis. BPC 157 increases the production of hepatocyte growth factors (HGFs), which stimulate cell proliferation and promote tissue repair. It also upregulates genes involved in wound healing.